We show that depletion of WT Kras in Kras mutant mice facilitates tumorigenesis in the pancreas yet was not sufficient to drive progression to PDAC, suggesting that WT KRAS acts to restrain mutant KRAS signaling but does not act as tumor suppressor in pancreatic cancer. Here, KRAS is linked to pancreatic neoplasm.